Samson Tom

Samson Tom is an accomplished executive with extensive leadership experience in the biotechnology and medical industries. Currently serving as President and CEO of Britecyte, Inc. since June 2022, Samson previously held positions including Vice President of Science & Clinical at Kelly and General Manager at Smith+Nephew. Notably, Samson's career includes roles as President and CEO of Osiris Therapeutics and Vice President of R&D at Bioventus. With a solid foundation in research and development, Samson has also served in various senior roles at Johnson & Johnson and Osiris Therapeutics. Samson holds an MBA in General Management from The Johns Hopkins University - Carey Business School, a Ph.D. in Biochemistry, and a Master’s Degree in Biochemistry from the University of Rochester School of Medicine and Dentistry, along with a Bachelor’s Degree in Biology and Chemistry from Cornell University.